Lidocaine hydrochloride

SKU: orb1309622

Description

Lidocaine hydrochloride is a local anesthetic and Class Ib antiarrhythmic agent. It is widely used in research for in vitro electrophysiology studies and in vivo models to investigate sodium channel blockade, cardiac arrhythmias, and neuronal signaling. Its potency exceeds that of procaine but it has a shorter duration than bupivacaine.

Research Area

Cell Biology, Pharmacology & Drug Discovery, Signal Transduction

Key Properties

• CAS Number: 73-78-9
• MW: 270.798
• Purity: 98.00% (May vary between batches)
• Formula: C₁₄H₂₃ClN₂O
• SMILES: Cl.CCN(CC)CC(=O)Nc1c(C)cccc1C
• Target: MEK,Sodium Channel,ERK,Apoptosis,NF-κB
• Solubility: H2O:50 mg/mL (184.64 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (7.39 mM);DMSO:250 mg/mL (923.2 mM);Ethanol:54 mg/mL (199.41 mM)

Bioactivity

• In Vivo:
  Intravenous administration of the local anaesthetic lidocaine has been used to treat neuropathic pain for several decades and significantly improves postoperative pain associated with complex spine surgery and cholecystectomy. It is well established that lidocaine used for regional anaesthesia blocks impulses in peripheral nerves by inhibiting voltage-gated sodium (Na+) channels. Intravenous lidocaine has an analgesic effect on mechanical noxious response, decreases the spinal noxious response induced by peripheral pinch stimuli and the frequency of spontaneous excitatory postsynaptic currents(EPSCs) without changing their amplitude. It has no effect on spontaneous inhibitory postsynaptic currents and produces an outward current in SG neurons.
• In Vitro:
  Lidocaine above 1.25 g/l reduces cellular viability and triggers apoptosis in HCE cells in a time- and dose-dependent manner. Lidocaine-induced apoptosis is caspase dependent and may be related to mitochondrial pathway. Lidocaine, at the level of tissue concentration under topical or local administration, also has a direct inhibitory effect on the activity of epidermal growth factor receptor (EGFR), which is a potential target for antiproliferation in cancer cells.
• Cell Research:
  Cells at logarithmic phase are treated with lidocaine hydrochloride at concentrations (w/v) from 10 to 0.15625 g/l in step dilutions. HCE cells without lidocaine treatment are used as controls. The morphology and growing status of the cells are monitored every 4 hr.(Only for Reference)

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Extracellular signal regulated kinases, ERK, MEK, MAP2K, MAPKK, Inhibitor, inhibit, Lignocaine, Lignocaine Hydrochloride, Lignocaine hydrochloride, Lidocaine, Lidocaine HCL, Lidocaine hydrochloride, Lidocaine Hydrochloride, Lidothesin, Mitogen-activated protein kinase kinase, Na+ channels, Na channels, NFκB, NF-kB, NFkB, Nuclear factor-kappaB, Nuclear factor-κB, NF-κB, Apoptosis, SodiumChannel, Sodium Channel, Xyloneural

Compound Identifiers

PubChem CID

6314